News

The American Society of Clinical Oncology (ASCO) recently created the ASCO Center for Equity, Diversity, and Inclusion, which is designed to promote equity, diversity, and inclusion (EDI) goals across the organization and throughout the wider...

An analysis of internal processes by physicians in a radiation oncology practice at Vanderbilt University Medical Center determined that the time and cost burdens of treatment-related prior authorizations for such practices are substantial...

Black patients reported significantly greater general pain both before the initiation of radiation therapy and at the end of radiation therapy, according to an analysis of racial differences in thoracic radiation treatment and related...

Findings from a retrospective cohort study suggest that patients with metastatic, castration-resistant prostate cancer experience higher costs, and require more outpatient services, compared with those with nonmetastatic cancer.

Study findings suggest margetuximab plus chemotherapy is not cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast cancer.

Greater reliance on genomic assays has reduced the use of adjuvant chemotherapy in women with early-stage, HR–positive, HER2–negative breast cancer who are free of axillary node disease and at low genomic risk, according to a recent study.

Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.

Study findings demonstrate encouraging feasibility and initial acceptability of implementing an EHR-integrated symptom and needs screening and referral system among diverse oncology patients.

The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.

Patients with CLL or SLL who discontinued venetoclax as first-line therapy were older and had a greater disease burden and risk of tumor lysis syndrome when compared with those patients who completed at least 12 cycles of treatment, according...